Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Home Ventilation in Patients With Severe Hypercapnic Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD using Gold 2017 criterion~* Optimal medical treatment of COPD, ie. inhaled steroids, long-acting β2-agonist, long-acting anticholinergic, according to GOLD 2017 guidelines.~* At least one acute exacerbation of COPD with hypercapnic respiratory failure~* Introduction of NIV distant to acute exacerbation of COPD with persisting hypercapnia (\> 7kPa) on arterial blood gas at rest.~* NIV equipment from the service provider Don Du Souffle (DDS).~* Patient able to give their consent~Exclusion Criteria:~* Contraindication to NIV (consensus conference of SFAR-SPLF-SRLF)~* Obstructive sleep apnea with apnea/hypopnea index \> to 20/h~* BMI \> 35 kg/m2~* Low compliance with NIV treatment (\<3h per day)~* Acute exacerbation COPD during inclusion or pH \<7.30 in routine blood gas arterial~* Severe heart failure (New York Heart Association stage IV/IV)~* Unstable angina~* Severe arrhythmias~* Severe renal insufficiency stage \> 4~* Other conditions than COPD resulting in hypercapnia~* Pregnancy~* Patient without health insurance~* Patient excluded by another study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard mode (Type: None): after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV using Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
- Lowenstein mode (Type: None): after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV without Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.

Based on this trial design, predict the completion outcome and termination type (if applicable).